Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

Roche for the novel anti-cancer antibody TB-403 is also going well, as evidenced by the success fee that we received from them earlier in the year."

"ThromboGenics' business has never been so well placed. We have a clear strategy, an exciting lead product in microplasmin and two further assets in TB-402 and TB-403 which will provide us with further opportunities to deliver value for our shareholders."

    Financial Update

    - ThromboGenics achieved revenues of EUR3.6 million in the
      first half of 2009, nearly all of which came from a success fee from
      Roche, our partner for TB-403. R&D expenses were EUR8.8 million during
      this six month period. In addition EUR5.7 million of expenses related
      to the microplasmin Phase III clinical program (called MIVI TRUST) have
      been capitalized. General and administrative costs in the first half
      increased from EUR1.2 million to EUR1.7 million due to higher one-time
      legal costs, in part due to the merger of ThromboGenics NV and
      ThromboGenics Ltd. In the first half, ThromboGenics made a net loss of
      EUR4.7 million.

    - As of June 30, 2009, ThromboGenics had EUR52.6 million in
      cash and cash equivalents. This compares to EUR40.4 million on June 30,
      2008 and EUR58.9 million on December 31, 2008. The cash figure at the
      end of June includes the EUR3.1 million that ThromboGenics received in
      May as a result of the exercise of warrants. The Company's cash
      resources are expected to allow ThromboGenics to execute its current
      operational plans for approximately the next two years.


    Business Highlights
    Clinical Highlights

Microplasmin - Back of the Eye Disease: Phase III clinical program to evaluate non-surgical treatment of patients with vitreomacular adhesion.

    - Phase III program continues to progress well, with
      recruitment on track


'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
(Date:11/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a ... pharmaceutical company, today announced it has submitted an additional ... and Drug Administration (FDA), which brings the Company,s total ... eighteen submissions now pending at the FDA. ... the Company, commented, "Our team here at IGI has ...
(Date:11/24/2014)...  Last week, Representatives Gus Bilirakis ... a bold bipartisan step on behalf of patients ... Original co-sponsors of the legislation include Representatives McCaul ... drug makers and innovators to "repurpose" major market ... which opens the door to the development of ...
(Date:11/24/2014)... , November 24, 2014   ... on ScienceDirect   Elsevier , a world-leading ... is pleased to announce the launch of the latest title ... Current Opinion in Food Science . ... provide specialists with a new platform to keep up-to-date with ...
Breaking Biology Technology:La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... At a meeting of the,Board of ... ), held today, a dividend of ... outstanding shares of Preferred Stock was,declared ... stockholders of record at the close,of ...
... Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced ... ended September 30, 2007. Net,revenues totaled $7,373,770 for the ... period in 2006. Gross profit decreased by 2.66% due ... sales from Aida,s,transfusion and injection forms of etimicin sulfate ...
... Million Financing, WOBURN, Mass., Nov. 15 BioVex ... the treatment and,prevention of cancer and infectious disease, announced ... the completion of a,venture debt transaction, raising a total ... the capital to complete its preparations for, and,to commence, ...
Cached Biology Technology:Aida Files 10Q 2Aida Files 10Q 3Aida Files 10Q 4BioVex Closes Second Round of Series E Financing 2
(Date:11/6/2014)... -- A groundbreaking paper from a team of Florida ... of how plants could adapt to and survive environmental ... published in the latest issue of the journal ... (the complex of DNA and proteins) is organized in ... that some genes are turned on and others are ...
(Date:11/5/2014)... Santamaria, associate professor of biology in the UTSA ... in the nation selected to receive a two-year ... for Exploratory Research (EAGER). The funding supports President ... researchers to create new technology that will demystify ... complex behaviors in neuroscience are broken into the ...
(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3When less is more: Death in moderation boosts population density in nature 2
... critical for improving cancer survival rates. Yet, one of ... is notoriously difficult to detect in its early stages. ... lung cancer by merely shining diffuse light on cells ... study, the analysis technique--called partial wave spectroscopic (PWS) microscopy--was ...
... London, UK (October, 07, 2010) Many scientists aspire to take ... can grow organs and implants perfectly matched to each patient ... Tissue Engineering , published by SAGE-Hindawi, explains how engineering the ... working on them, can be as powerful an agent for ...
... Mont. -- Invasive plants make life tougher for farmers and ... Missouri River Basin, so why not turn the plants into ... Russian olive and saltcedar alone could supply biomass far into ... Converting invasive plants to fuel is an intriguing idea ...
Cached Biology News:Cheek swab may detect lung cancer 2Cheek swab may detect lung cancer 3Stem cells shape up to their surroundings 2Stem cells shape up to their surroundings 3Montana State, partners in 6 states consider converting invasive plants to fuel 2Montana State, partners in 6 states consider converting invasive plants to fuel 3Montana State, partners in 6 states consider converting invasive plants to fuel 4
6-(2,4-dinitrophenyl)aminohexanoic acid, succinimidyl ester (DNP-X, SE)...
Human/Mouse/Rat LAR Affinity Purified PAb...
Oligodendrocyte Marker O1 MAb (Clone O1)...
Griess Reagent component for determination of nitrite in aqueous solutions....
Biology Products: